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Context: Human chorionic gonadotropin (hCG) stimulates thyroid function during pregnancy. We
recently showed that thyroid autoimmunity severely attenuated the thyroidal response to hCG
stimulation and that this may underlie the higher risk of premature delivery in thyroperoxidase
antibody (TPOAb)-positive women. We hypothesized that a lower thyroidal response to hCG
stimulation in TPOAb-negative women is also associated with a higher risk of premature
delivery and preterm premature rupture of membranes (pPROM).
Design, Setting, and Participants: Thyrotropin (TSH), free thyroxine (FT4), and hCG concentrations
were available in 5644 TPOAb-negativewomen fromaprospective cohort.We tested for interaction
between TSH or FT4 and hCG in linear regression models for duration of pregnancy and logistic
regression models for premature delivery/pPROM. Accordingly, analyses were stratified per TSH
percentile (TSH $ 85th percentile) and hCG per 10,000 IU/L.
Results:Womenwith high TSH and low hCG concentrations did not have a higher risk of premature
delivery or pPROM, with protective effect estimates. In contrast, women with a high TSH con-
centration despite a high hCG concentration had twofold to 10-fold higher risk of premature
delivery (Pdifference = 0.022) and an up to fourfold higher risk of pPROM (Pdifference = 0.079). hCG
concentrations were not associated with premature delivery or pPROM.
Conclusion: In TPOAb-negative women with high-normal TSH concentrations, only women with
high hCG concentrations had a higher risk of premature delivery or pPROM. These results suggest a
lower thyroidal response to hCG stimulation is also associated with premature delivery in TPOAb-
negative women and that an additional measurement of hCG may improve thyroid-related risk
assessments during pregnancy. (J Clin Endocrinol Metab 102: 3360–3367, 2017)
Thyroid hormone (TH) regulates numerous metabolicprocesses that are important for an uncomplicated
pregnancy course. During early pregnancy, human cho-
rionic gonadotropin (hCG) stimulates the thyrotropin (TSH)
receptor, which leads to an increase in free thyroxine
(FT4) concentrations and a subsequent decrease in TSH
concentrations (1, 2). We recently demonstrated that
thyroperoxidase antibody (TPOAb)-positive women had
an impaired response to thyroidal stimulation by hCG (3).
In that study, we also showed that TPOAb-positive women
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with a lower thyroidal response to hCG stimulation had a
higher risk of premature delivery. However, even in
TPOAb-negative women, subgroups of women may have
an impaired response to hCG. This may include women
with isolated thyroglobulin antibody positivity, as occurs in
up to 25% of women with thyroid autoimmunity (4).
Furthermore, the presence of TSH receptor-blocking
antibodies, a history of thyroid infection, or exposure to
thyrotoxic treatments (i.e., specific drugs or previous ir-
radiation of the neck) may affect thyroid functional ca-
pacity in TPOAb-negative women.
hCG is a major determinant of gestational thyroid
function but has a notoriously versatile pattern throughout
early pregnancy. hCG is undetectable before conception,
but after conception, hCG rapidly rises to high concen-
trations until approximately the ninth to the 12th week,
after which it steadily declines during the remainder of
pregnancy (5). Gestational hCGconcentrations have a large
within-individual variability and also exhibit clear between-
individual differences when measured at the same time
point (5). This leads to high inter- and intraindividual
variabilities in the extent of thyroidal stimulation by hCG.
Although a recent study from our group indicated that an
impaired thyroidal response to hCG in TPOAb-positive
women is a risk factor for premature delivery, it remains
unknownwhether a suboptimal thyroidal response to hCG
stimulation in TPOAb-negative women is of clinical rele-
vance and/or is a risk factor for premature delivery.
Overt as well as mild forms of maternal thyroid dys-
function have been associated with a higher risk of pre-
mature delivery (6–10). Risk estimates for premature
delivery in women with subclinical hypothyroidism and
hypothyroxinemia differ widely between studies and vary
from a 30% lower risk to a 3.3-fold higher risk (11–16). It
has been hypothesized that these between-study differences
are a consequence of variations in population characteris-
tics, such as TPOAb positivity, iron status, ethnicity, body
mass index (BMI), parity, and smoking status (17–23).
Interestingly, all of these population characteristics are
important determinants of hCGconcentrations during early
pregnancy (5). Moreover, we recently showed that women
with subclinical hypothyroidism had a lower thyroidal
response to hCG stimulation regardless of their TPOAb
status or BMI (24). Therefore, we hypothesized that even in
TPOAb-negative women, lower thyroidal stimulation by
hCG is associated with a higher risk for premature delivery
and preterm premature rupture of membranes (pPROM), a
major risk factor for premature delivery.
Materials and Methods
To investigate this hypothesis, we determined hCG concen-
trations in the Generation R Study, a population-based
prospective cohort from early fetal life onward in Rotterdam,
The Netherlands (25). We previously reported on the associ-
ation between TSH or FT4 concentrations and the risk of
premature delivery in this population (26). In the same pop-
ulation, we investigated whether the addition of hCG during
early pregnancy improved the interpretation of maternal TSH
and FT4 concentrations for the risk assessment of prema-
ture delivery (26). Populations for analyses, covariates, and
definitions of outcomes have been described previously (26). In
short, 6264 pregnant women had data available during early
pregnancy on TSH, FT4, or TPOAb concentration and
pregnancy duration or pPROM. We excluded women with
twin pregnancies (N = 128), preexisting thyroid disease or
thyroid-interfering medication usage (N = 89), women who un-
derwent fertility treatment (N = 76), TPOAb-positive women
(N = 312), and women with hCG measurements that were not
performed within the same week as thyroid function mea-
surements (N = 15). Premature delivery was defined as a
pregnancy duration ,37 weeks, and spontaneous premature
delivery was defined as not having had a delivery after in-
duction of labor or by an elective caesarean section. pPROM
was defined as ruptured membranes before 37 weeks’ gesta-
tion. All analyses on premature delivery were adjusted for
maternal age, BMI, smoking, parity, education level, ethnicity,
height, and fetal sex.
We performed various sensitivity analyses: (1) Because the
cutoff for the effects of thyroid autoimmunity on thyroidal
stimulation by hCG may be lower than currently used TPOAb-
positivity cutoffs (e.g., 60 IU/L for our assay), we additionally
excluded women with TPOAbs.10 IU/L. (2) Preeclampsia is a
risk factor for premature delivery and may be associated with
specific combinations of hCG and FT4 (27); therefore, we also
excluded women with preeclampsia. (3) Spontaneous prema-
ture delivery may be a better reflection of the underlying biology;
therefore, we also excluded women with nonspontaneous pre-
mature delivery.
During the peer review process, additional analyses were
performed in the full data set (including TPOAb-positive women)
to investigate whether TSH is a less sensitive marker in TPOAb-
positive women than in TPOAb-negative women. To do so, we
compared the association of FT4 with TSH concentrations in
TPOAb-positive vs TPOAb-negative women. These analyses
were subsequently added to the supplemental material.
Statistical analysis
To fulfill model assumptions, TSH values were logarith-
mically transformed. We used linear or logistic regression
models with restricted cubic splines with three knots to assess
nonlinearity of the associations between TSH, FT4, hCG, and
gestational age or (spontaneous) premature delivery and
pPROM. Subsequently, linear or logistic regression models
were built accordingly. To test the hypothesis that a high hCG
level helps to distinguish women with a high TSH or low FT4
concentration and a high risk of premature delivery, we
stratified the association between high TSH and/or low FT4
concentration and premature delivery according to hCG level.
To investigate whether the association between continuous TSH
and/or FT4 concentration and premature delivery or pPROM
differs according to hCG concentrations, we tested for in-
teraction by adding a product term of TSH or FT4 and hCG
to the model. The identification of clinically relevant effect
modification requires more statistical power; therefore, we
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considered interaction terms with a P value ,0.15 for assess-
ment of clinical relevance by subsequently stratifying analyses.
We performed a similar interaction analysis in which hCG was
replaced with gestational age at blood sampling because ges-
tational age is considered a marker of hCG concentrations and
has therefore been used in other clinical studies on gestational
thyroid function. Removal of outliers for TSH, FT4, or hCG did
not change the results.
For variables with missing data, multiple imputations
according to the Markov chain Monte Carlo method were used
(28). Five imputed data sets were created and pooled for ana-
lyses. For the prematurity database, TSH, FT4, hCG, smoking,
socioeconomic status, ethnicity, parity, BMI, fetal sex, and
gestational age at blood sampling were added to the model
(missing because of nonresponse/nonrecording in 6.3%,
5.7%, 3.5%, 12.8%, 7.2%, 5.7%, 1.9%, and all other vari-
ables ,2.0%, respectively). Furthermore, we added maternal
age, total T4, and TPOAb concentrations as prediction vari-
ables during the multiple imputation procedure only. No sig-
nificant differences in descriptive characteristics were found
between the original and imputed data sets. All statistical an-
alyses were performed using R statistical software v3.03
(package rms, visreg) or Statistical Package of Social Sciences
v20.0 for Windows (SPSS v22.0; IBM Corp, Armonk, NY).
Results
The final study population comprised 5644 women
(Fig. 1), descriptive characteristics of whom are shown
in Table 1. The association of TSH concentrations with
mean duration of pregnancy, premature delivery, and
pPROM differed between women with low hCG con-
centration and those with high hCG concentration at the
time of TSHmeasurement (Pinteraction = 0.039, 0.022, and
0.079, respectively; Supplemental Table 1). Heatmaps
graphically illustrate the differences in mean gestational
age [Fig. 2(a)], the risk of premature delivery [Fig. 2(b)],
and the risk of pPROM [Fig. 2(c)] according to the
combination of hCG and TSH in the whole study pop-
ulation (blue indicates a lower mean gestational age, lower
risk of premature delivery, or lower risk of pPROM, and
red indicates a higher mean gestational age, higher risk of
premature delivery, or higher risk of pPROM).
To quantify the differences in risks, we stratified the
association of high TSH concentration (per percentile)
with premature delivery for hCG concentration (per
10,000 IU/L; Table 2). Women with high TSH and low
hCG concentrations did not have a higher risk of pre-
mature delivery, and most effect estimates pointed
toward a protective effect [Fig. 2(b); Table 2]. In contrast,
women with a high TSH concentration despite a high
hCG concentration had a twofold to 10-fold higher risk
of premature delivery depending on the cutoffs used
(Fig. 2; Table 2).
A similar analysis for pPROM showed that women
with high TSH and low hCG concentrations did not
have a higher risk of pPROM, and most effect estimates
pointed toward a protective effect [Fig. 2(c); Table 3]. In
contrast, womenwith a high TSH concentration despite a
high hCG concentration had a risk of pPROM that
ranged between a protective effect and a fourfold higher
risk depending on the cutoffs used (Fig. 2(c); Table 3).
In the whole population, the association of FT4 con-
centration with premature delivery did not differ between
low or high hCG concentrations (Pinteraction = 0.52,Figure 1. Flowchart exhibiting the selection of the study population.
Table 1. Descriptive Statistics of the Study
Population
Median (95% Range)
Median TSH, mU/L 1.33 (0.05–4.13)
Median FT4, pmol/L 14.8 (10.3–22.3)
Median hCG, IU/L 44.625 (11.999–106.339)
Median UIC, mg/ga 273 (96–777)
Gestational ageb 13.4 (9.6–17.6)
Maternal age, y 30.3 (19.5–38.8)
Maternal height, cm 168 (153–182)
Maternal BMI, kg/m2 23.5 (18.5–38.8)
N (%)
Premature delivery, ,37 wkb 276 (4.9)
Parityb
0 3226 (57.2)
1 1681 (29.8)
$2 738 (13.1)
Smokingb
Nonsmokers 4140 (73.4)
Stopped smokers 506 (9.0)
Smokers 997 (17.7)
Education levelb
Low 606 (10.7)
Middle 2599 (46.0)
High 2439 (43.4)
Ethnicityb
Dutch 2803 (51.6)
Moroccan 341 (6.3)
Turkish 455 (8.4)
Surinamese 479 (8.8)
Other Western 491 (9.0)
Other non-Western 866 (15.9)
Child sex (boys %)b 2853 (50.5)
Abbreviation: UIC, urinary iodine to creatinine ratio.
aBased on data from a subset of N = 1031 women.
bAt time of blood sampling; data shown in weeks.
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0.69, and 0.68 for mean duration of pregnancy, premature
delivery, and pPROM, respectively; Supplemental Table 1).
Similar results were obtained when women with TPOAb
concentrations above a lower cutoff (e.g., 10 IU/L) were
excluded, after womenwith preeclampsia were excluded,
or when analyses were restricted to women with a
spontaneous delivery (data not shown). hCG concen-
trations were not associated with the duration of preg-
nancy, premature delivery, or pPROM. The association
of TSH or FT4 concentrationwith premature delivery did
not differ by gestational age at blood sampling, used as a
potential proxy for hCG (data not shown), or by fetal sex
(data not shown).
In the total population (including TPOAb-positive
women), the association of FT4 with TSH differed be-
tween TPOAb-negative and TPOAb-positive women
(P , 0.001; Supplemental Fig. 1). At similar FT4 con-
centrations in the lower range, TPOAb-positive women
had higher TSH concentrations with a considerably
higher spread than TPOAb-negative women (Supple-
mental Fig. 1).
Discussion
In the current study, we demonstrated that the associa-
tion of maternal thyroid function during pregnancy with
the risk of premature delivery in TPOAb-negative women
was modified by hCG concentration. Our main finding is
that womenwith a high TSH concentration despite a high
hCG concentration had a twofold to 10-fold higher risk
of premature delivery and a 1.6- to 4.2-fold higher risk of
pPROM. In contrast, women with high TSH and low
hCG concentrations had a lower or normal risk of pre-
mature delivery.
Suboptimal placental function is an important risk
factor for premature delivery (29–31). TH transporters
and receptors are abundantly expressed in the placenta
(32–34), and TH regulates the secretion of several growth
factors and cytokines implicated in placental develop-
ment (33, 35–37). Crucial stages of placental develop-
ment coincide with the peak in hCG concentrations
during the late first and early second trimesters (5, 38).
Therefore, we speculated that a suboptimal thyroidal
response to hCG stimulationwas associatedwith a higher
risk of premature delivery because it causes a relative TH
shortage during early pregnancy. We previously showed
that the thyroidal response to hCG stimulation was
considerably impaired in TPOAb-positive women and
that TPOAb-positive women with a low thyroidal re-
sponse to hCG in particular had a higher risk of pre-
mature delivery (3). The results of the current study in
TPOAb-negative women further strengthen the concept
that a lower thyroidal response to hCG stimulation
Figure 2. (a) Mean gestational age at birth, (b) risk of premature
delivery, and (c) risk of premature rupture of membranes according
to TSH and hCG concentrations. Heatmaps show hCG on the x-axis,
TSH on the y-axis, and the mean gestational age of risk of
premature delivery on the z-axis, which ranges from low values or
risks (blue) to high levels or risks (red).
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increases the risk of premature delivery. Alternatively, an
attenuated thyroidal response to hCG stimulation could be
associated with premature delivery because it lowers the
total TH availability during pregnancy (e.g., a lower area
under the curve). Further studies, preferably using re-
peated measurements of hCG and thyroid function, are
required to further elucidate these mechanisms.
As for the cause of a lower thyroidal response to hCG
stimulation, the subset of TPOAb-negative women in the
current study may still be subject to a form of thyroidal
autoimmunity (e.g., reflected by isolated thyroglobulin
antibody positivity or because of the presence of blocking
TSHreceptor antibodies).Unfortunately, thesemeasurements
were not available in our pregnancy cohort. Although the
current results were not altered after the exclusion of
womenwith very lowTPOAbconcentrations (e.g.,.10 IU/L),
further studies are required to identify risk factors
for lower thyroid functional capacity in TPOAb-negative
women, such as previous thyroiditis, exposure to thyro-
toxic treatments, or natural variation in thyroid functional
capacity through genetic variability. Regarding the latter,
various partial loss-of-function mutations in the TSH re-
ceptor have been described (39), and such mutations could
potentially also interfere with TSH receptor stimulation by
hCG. Furthermore, more commonly occurring single nu-
cleotide polymorphisms (SNPs) in the TSH receptor may
Table 3. Outline of the Interaction Between hCG and TSH in the Risk of Premature Rupture of Membranes
TSH Percentile
(Value in mU/L)
hCG Concentration, IU/L
Overall <20,000
20,000–
30,000
30,000–
40,000
40,000–
50,000
50,000–
60,000
60,000–
70,000 >70,000
$96 (4.02) 1.24 (0.60–2.55) a a 1.48 0.70 1.31 1.63 4.20
$95 (3.72) 1.10 (0.54–2.25) a a 1.11 0.62 1.14 1.13 4.31
$94 (3.49) 0.94 (0.47–1.89) a a 0.90 0.55 0.85 0.96 3.33
$93 (3.32) 0.97 (0.51–1.84) a a 0.80 1.13 0.75 0.78 3.24
$92 (3.15) 0.90 (0.51–1.62) a a 0.71 0.96 0.62 0.76 3.83
$91 (3.01) 0.81 (0.47–1.43) a 0.08 0.70 0.87 0.52 0.68 3.44
$90 (2.91) 0.84 (0.50–1.44) a 0.09 0.60 0.95 0.54 0.65 3.74
$89 (2.81) 0.82 (0.48–1.40) a 0.01 0.75 0.82 0.50 0.62 3.54
$88 (2.73) 0.90 (0.55–1.46) 0.42 0.01 0.68 0.91 0.46 1.55 3.36
$87 (2.66) 0.97 (0.59–1.59) 0.61 0.39 0.64 0.87 0.69 1.40 3.38
$86 (2.59) 0.94 (0.57–1.53) 0.58 0.39 0.81 0.81 0.61 1.32 3.25
$85 (2.53) 0.91 (0.55–1.49) 0.79 0.36 0.77 0.84 0.55 1.22 2.92
Adjusted odds ratios are shown for premature rupture of membranes (,37 weeks) according to different percentile cutoffs for TSH, stratified by
concomitant hCG levels. All analyses were adjusted for maternal age, smoking, education level, ethnicity, parity, BMI, height, and fetal sex. hCG cutoff
groups were not associated with the risk of premature rupture of membranes.
aNone of the women in this subgroup had a premature delivery; too little pPROM occurred to do reliable analyses for a cutoff for hCG .80,000 IU/L.
Table 2. Outline of the Interaction Between hCG and TSH in the Risk of Premature Delivery
TSH Percentile
(Value in mU/L)
hCG Concentration, IU/L
Overall <20,000
20,000–
30,000
30,000–
40,000
40,000–
50,000
50,000–
60,000
60,000–
70,000
70,000–
80,000 >80,000
$96 (4.02) 1.88 (1.14–3.12) a a a 0.74 1.54 3.42 5.91 9.96
$95 (3.72) 1.62 (0.98–2.67) 0.64 a 0.52 0.57 1.15 2.34 4.46 6.84
$94 (3.49) 1.50 (0.95–2.35) 0.46 a 0.53 0.83 1.06 1.93 2.77 6.29
$93 (3.32) 1.40 (0.92–2.12) 0.40 0.41 0.42 0.73 0.88 1.82 2.48 5.64
$92 (3.15) 1.28 (0.85–1.92) 0.33 0.38 0.61 0.60 0.67 1.67 2.16 5.05
$91 (3.01) 1.18 (0.79–1.74) 0.53 0.42 0.54 1.00 1.00 1.60 2.20 4.02
$90 (2.91) 1.24 (0.85–1.80) 0.48 0.39 0.49 0.93 0.95 1.48 3.36 3.33
$89 (2.81) 1.16 (0.80–1.69) 0.51 0.37 0.44 0.87 0.89 1.42 2.41 3.05
$88 (2.73) 1.23 (0.87–1.75) 0.61 0.34 0.39 0.79 0.82 2.60 3.79 2.68
$87 (2.66) 1.22 (0.85–1.74) 0.80 0.38 0.39 0.88 1.08 2.39 2.59 2.56
$86 (2.59) 1.16 (0.82–1.64) 0.72 0.50 0.36 0.86 0.91 2.07 2.59 2.29
$85 (2.53) 1.10 (0.77–1.56) 0.89 0.48 0.35 0.96 0.83 1.89 2.22 1.85
Adjusted odds ratios are shown for premature delivery (,37 weeks) according to different percentile cutoffs for TSH concentrations, stratified by
concomitant hCG levels. All analyses were adjusted for maternal age, smoking, education level, ethnicity, parity, BMI, height, and fetal sex. hCG cutoff
groups were not associated with the risk of premature delivery.
aNone of the women in this subgroup had a premature delivery.
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account for some of the variability in TSH receptor stim-
ulation by hCG (40). Although a large genome-wide as-
sociation study demonstrated thatTSHSNPs identified in a
population of nonpregnant individuals were also associ-
ated with TSH during pregnancy, no SNPs in the TSH
receptor were identified (41).
Our results suggest that a measurement of hCG
concentrations during pregnancy may improve the in-
terpretation of (high) TSH concentrations, although it is
less likely to improve the interpretation of FT4 concen-
trations. The discrepancy between our results on TSH
and FT4 may be explained by the fact that the relative
changes in TSH concentrations during pregnancy are
larger than the changes in FT4 concentrations, given the
log-linear relationship between FT4 and TSH. As such,
higher TSH concentrations may better reflect a relative
TH shortage.
Intriguingly, in a previous paper, our group demon-
strated that FT4 response to hCG may be relevant in
determining the risk of premature delivery in TPOAb-
positive women (3). In that study, we demonstrated that
the risk of premature delivery in TPOAb-positive women
was best distinguished by the combination of hCG and
FT4, rather than hCG and TSH. Additional analyses in
the current paper indicate that TSH was a less-sensitive
marker for FT4 in TPOAb-positive women than in
TPOAb-negative women. Although both of these studies
require replication, the results from the current study on
the combination of high TSH and high hCG concen-
trations also indicated that a suboptimal thyroid response
to hCG stimulation (e.g., a deviation from the naturally
occurring physiology) is a risk factor for premature
delivery.
The risk of premature delivery in women with sub-
clinical thyroid dysfunction has been investigated in
many different populations. Taken together, these studies
report a wide range in the risk of premature delivery,
from a 30% decrease to a 3.3-fold increased risk (11–16).
The results from our study suggest that such large
between-study differences in the risk of premature de-
livery for women with subclinical thyroid dysfunction
may be due to between-study differences in hCG con-
centrations at the time of thyroid function measurement.
Unfortunately, none of the studies that investigated the
association of maternal thyroid function with premature
delivery had hCG measurements available.
Although gestational age at blood sampling may be a
proxy for hCG, we could not identify a difference in the
association of TSH or FT4 concentration with premature
delivery according to a different gestational age at blood
sampling in our study; this is most likely because of the
large interindividual variations in hCG concentrations.
Furthermore, we were unable to replicate the results of
other studies by selecting only subjects with the same
gestational (i.e., 10 to 13 weeks, 10 3/7 to 13 6/7 weeks,
and ameanof 14.1weeks in three other studies) (11, 16, 42).
Therefore, gestational age at presentation is unlikely to
be a good proxy for hCG given the large interindividual
differences in hCG concentrations. Future studies are
needed to verify if the observed differences in risk estimates
between populations are due to differences in population
hCG concentrations or differences in other factors af-
fecting thyroidal stimulation.
In this study, we were able to investigate differences in
the association of thyroid function with the risk of pre-
mature delivery in a large population with detailed data
and pregnancy outcomes that rendered adequate statisti-
cal power to detect an overall difference while adjusting
for potential confounders. One potential limitation of the
current study is that we used an assay that measured total
hCG concentrations, including the various isoforms such as
nicked, asialo-, and hyperglycosylated hCG. It has been
shown that hCG subtypes have different thyrotropic ac-
tivities (43–45). Although different ratios of hCG isoforms
have been reported in pathologic conditions such as pre-
eclampsia (46, 47), we were unable to further distinguish
between possible effects of the different isoforms. Such
distinctions may prove valuable in future efforts to describe
women at high risk for premature delivery and/or pPROM.
Also, we were limited because the size of our study pop-
ulation did not allow us to stratify analysis using mutually
exclusive groups of women with high TSH concentrations.
However, continuous interaction analysis showed that the
overall difference between the groups was statistically sig-
nificant, and we were able to prove heatmaps of these risk
estimates.
In conclusion, we showed that the risk of premature
delivery according to TSH concentrations was modified
by hCG concentrations. Among all TPOAb-negative
women with high-normal TSH concentrations, only
those with high hCG concentrations at the time of TSH
measurement had a higher risk of premature delivery.
These data suggest that the assessment of maternal
thyroid function together with hCG concentrations can
improve the risk assessment of premature delivery and
give insights into the pathophysiology of the association
between maternal thyroid function and premature de-
livery.When further replicated, this conceptmay improve
clinical practice by facilitating identification of women at
risk for pregnancy complications.
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